Gemcitabine-cisplatin plus durvalumab in advanced intrahepatic cholangiocarcinoma: effectiveness outcomes and characterization of the tumor microenvironment - PubMed
6 hours ago
- #Intrahepatic Cholangiocarcinoma
- #Tumor Microenvironment
- #Immunotherapy
- Gemcitabine-cisplatin plus durvalumab showed encouraging efficacy and acceptable safety in advanced intrahepatic cholangiocarcinoma (ICC), achieving a median overall survival of 13.0 months and a 15.2% R0 resection rate.
- Early objective response (complete/partial) and successful conversion to R0 resection were associated with significantly longer overall survival, indicating potential for curative-intent surgery in a subset of patients.
- Transcriptomic and immunofluorescence analyses revealed tumor microenvironment remodeling, including increased PD-L1 expression and CD8+ T-cell infiltration, along with reduced α-SMA, suggesting immune activation and stromal changes as mechanisms underlying treatment sensitivity.